Target Audience

  • Researchers, healthcare professionals, and readers interested in biobanking and genomic medicine who want to understand the origins, development, and current status of BioBank Japan (BBJ).
  • Professionals in the life sciences and pharmaceutical industries who want to understand the differences between BBJ and UK Biobank, including their respective strengths and limitations as research infrastructures.
  • Readers interested in the research use of large-scale biomedical data and biological samples, long-term relationships with research participants, and the sustainability of research infrastructure.

Executive Summary

  • BioBank Japan (BBJ) was established in 2003 to advance personalized medicine in Japan and has become one of the world's largest disease-oriented biobanks.
  • While UK Biobank focuses on the long-term follow-up of population-based volunteers, BBJ was designed to recruit large numbers of patients with specific diseases and link their genetic information with detailed clinical data.
  • As of April 1, 2026, BBJ had accumulated data from approximately 270,000 patients, covering 51 diseases and approximately 440,000 registered disease cases. It has contributed to genomic research, disease mechanism studies, and genetic risk prediction.
  • BBJ is currently expanding whole-genome sequencing and multi-omics analyses, improving access to research resources, developing two-way communication with participants, and strengthening collaboration with other biobanks.
  • Looking ahead, the key challenge is to transform its extensive collection of biological samples and data into a sustainable, accessible research infrastructure that supports the translation of scientific discoveries into diagnostics, prevention, treatment, and drug development.

1. What Is BioBank Japan (BBJ)?

BioBank Japan (BBJ) was established in 2003 to advance personalized medicine in Japan. It has since become one of the world's largest disease-oriented biobanks.

Although BBJ and the UK's UK Biobank (UKB) were conceived around the same period, their underlying research designs differ substantially.

  • UK Biobank is a research infrastructure that emphasizes long-term follow-up of population-based volunteers to investigate how genetic, lifestyle, and environmental factors contribute to disease development.
  • BBJ focuses on recruiting large numbers of patients who already have specific diseases and linking their genetic information with detailed clinical data to investigate disease mechanisms, identify biomarkers, and support the development of treatments.

BBJ has evolved from an initially time-limited research project into a nationwide research infrastructure that has operated for more than two decades.

Key Facts About BBJ

According to official BBJ figures as of April 1, 2026, the scale of its research infrastructure is as follows. [1][2]

Item Scale
Establishment and project launch 2003
Registered patients Approximately 270,000
Diseases covered 51
Cumulative registered disease cases Approximately 440,000

The approximately 440,000 disease cases do not represent 440,000 unique individuals. The total includes patients registered for more than one disease.

BBJ's development can be broadly divided into three phases.

  1. 2003–2012: Infrastructure development and genetic discovery
    BBJ collected DNA, serum samples, and clinical information from large numbers of patients to support research identifying disease-associated genetic variants.

  2. 2013–2022: Expansion and utilization of research resources
    BBJ established a second patient cohort, accumulated follow-up information, expanded genomic datasets, and promoted access to research resources for external researchers and companies.

  3. 2023 onward: Data enrichment and two-way engagement
    BBJ has been strengthening whole-genome sequencing, multi-omics research, collaboration with other biobanks, and ongoing communication with research participants.

Today, a central challenge is not simply to increase the number of biological samples collected, but to transform its extensive existing resources into a sustainable, accessible research infrastructure with greater clinical and scientific value.

This assessment is based on BBJ's stated priorities for its fifth project phase and the research infrastructure development policies of the Japan Agency for Medical Research and Development (AMED). [1][4]

2. How Was BBJ Conceived and Established?

2.1 From the Human Genome Project to Personalized Medicine

In the early 2000s, the Human Genome Project was beginning to reveal the overall structure of the human genome.

At that time, personalized medicine attracted increasing attention as a major direction for biomedical research.

The central idea was to understand genetic differences between individuals and use this knowledge to predict disease susceptibility and responses to medications.

However, information about DNA sequences alone was insufficient to identify the genetic factors associated with actual diseases.

Researchers needed large numbers of patients whose DNA could be linked to their clinical information.

To address this challenge, Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT) launched the Project for Realization of Personalized Medicine in April 2003.

BBJ was established at the Institute of Medical Science, The University of Tokyo, as part of this national research initiative. [1][3]

2.2 BBJ's Original Research Design

A defining feature of BBJ was its decision to recruit patients with specific diseases rather than construct a cohort intended to represent the general population.

The first project phase aimed to collect DNA, serum samples, and clinical information from approximately 200,000 patients across 47 diseases, with the cooperation of medical institutions throughout Japan.

By collecting sufficiently large numbers of cases for individual diseases, researchers could improve the statistical power of studies identifying disease-associated genetic variants and genetic factors related to drug responses.

Between fiscal years 2003 and 2007, BBJ successfully recruited approximately 200,000 patients through 12 cooperating medical institutions encompassing 65 facilities. [1][3]

In other words, BBJ did not begin primarily as a system for tracking healthy individuals to study future disease development.

Instead, it was designed as a hospital-based research infrastructure connecting genetic information from large numbers of patients with their diseases and clinical characteristics.

3. The Development of BBJ: From Establishment to the Present

3.1 FY2003–FY2007 | Phase 1: Building the Research Infrastructure

BBJ began as part of the Project for Realization of Personalized Medicine.

During this period, it recruited approximately 200,000 patients across 47 diseases and collected DNA, serum samples, and clinical information.

The principal achievement of this phase was the establishment of large-scale disease-specific patient cohorts and an infrastructure for storing biological samples. [1][3]

3.2 FY2008–FY2012 | Phase 2: Data Accumulation and Genetic Discovery

During the second phase, BBJ placed greater emphasis on collecting and analyzing serum samples, clinical information, and prognostic data from existing participants rather than substantially expanding new recruitment.

Research using genome-wide association studies (GWAS) progressed, identifying genetic variants associated with disease susceptibility and drug responses. [1]

3.3 FY2013–FY2017 | Phase 3: Establishing the Second Cohort

During the third phase, BBJ recruited approximately 67,000 additional patients.

Recruitment covered 38 diseases, including some that overlapped with diseases targeted in the earlier cohort.

In 2014, BBJ added facilities for serum and plasma storage and established a tissue bank.

Beginning in 2015, it also started accepting samples from cancer clinical research groups. [1]

3.4 FY2018–FY2022 | Phase 4: Shifting from Collection to Utilization

By the fourth phase, BBJ had expanded to approximately 267,000 patients across 51 diseases.

The focus increasingly shifted toward making its extensive research resources available for scientific use.

BBJ promoted access to DNA samples, serum samples, and clinical information while continuing to generate genomic datasets.

From fiscal year 2018, related AMED programs supported efforts to strengthen BBJ's role as a biobank serving a broader community of researchers. [1][4]

3.5 FY2023 Onward | Phase 5: Multi-Omics and Two-Way Engagement

In its fifth phase, BBJ has been expanding its research infrastructure beyond genomic analysis to integrate other omics data, including blood metabolites and proteins.

In November 2024, BBJ launched "Minna no BBJ" (Everyone's BBJ), a website for research participants.

In January 2025, it began recruiting eligible existing participants for a new two-way biobank project designed to support ongoing engagement. [1][6]

3.6 FY2026 | Strengthening Nationwide Biobank Collaboration

In April 2026, AMED launched "B-cure NEXT," a successor to the previous B-cure initiative.

The program emphasizes collaboration among Japan's major biobanks, including BBJ, and the integration of genomic, omics, and clinical information to support practical applications in drug discovery and diagnostics. [5]

3.7 How Has BBJ's Role Changed?

An important observation from this history is that BBJ has not remained simply a repository of patient samples.

Instead, its role has evolved in response to technological advances and changing research needs.

Initially, the central objective was to collect DNA and identify disease-associated genetic variants.

Today, the emphasis has increasingly shifted toward integrating clinical, genomic, and multi-omics information into a research platform that can support a wide range of biomedical studies.

4. BBJ's Current Scale and Distinctive Features

4.1 Research Resources Available at BBJ

According to BBJ's official figures as of April 1, 2026, the research infrastructure includes the following resources. [2]

Item Scale
Registered patients Approximately 270,000
Diseases covered 51
Registered disease cases Approximately 440,000
DNA samples Approximately 800,000 tubes (from approximately 270,000 individuals)
Serum samples Approximately 1.7 million tubes (from approximately 200,000 individuals)
SNP data Approximately 270,000 individuals
Whole-genome sequencing data Approximately 16,000 individuals
Metabolomics data Approximately 43,830 individuals
Proteomics data Approximately 3,050 individuals

DNA and serum figures refer to the number of stored sample tubes, whereas genomic and omics figures refer to the number of individuals analyzed.

A particularly important point is that SNP data have been generated for approximately 270,000 individuals, while whole-genome sequencing and proteomics analyses currently cover smaller subsets of participants.

This suggests that BBJ has substantial potential to increase the scientific value of its existing resources through additional analyses.

4.2 Feature 1: A Hospital-Based, Disease-Oriented Biobank

Participants are recruited through cooperating medical institutions.

Their biological samples are linked to clinical information, including diagnoses, laboratory results, and treatment histories.

This design is particularly suitable for studying specific diseases in depth, including lifestyle-related diseases, cancer, and autoimmune diseases.

However, because participants are not randomly selected from the general population, researchers must exercise caution when generalizing findings to the Japanese population as a whole. [3]

4.3 Feature 2: Long-Term Follow-Up Information

BBJ has not limited its activities to collecting biological samples and clinical information at a single point in time.

It has also conducted ongoing collection of clinical information and follow-up studies of patient outcomes.

A study published in 2017 reported a follow-up rate of 97% and an average follow-up period of 7.7 years for prognostic follow-up covering 32 diseases in the first cohort.

Current official BBJ materials indicate that the average follow-up period exceeds 10 years. [2][3]

These longitudinal data make it possible to investigate relationships between genetic factors and disease progression, mortality risk, and outcomes following treatment.

4.4 Feature 3: A Major Resource for East Asian and Japanese Genomic Research

Historically, genomic research has been disproportionately based on populations of European ancestry.

BBJ provides a major source of large-scale genomic data from Japanese patients.

Its resources are particularly valuable for identifying genetic variants relevant to Japanese populations, validating genetic risk prediction models, and conducting comparative studies with international biobanks.

4.5 Feature 4: Stored Samples Can Be Reanalyzed Using New Technologies

Another important strength of BBJ is its extensive collection of stored DNA and serum samples.

These resources can be analyzed using technologies that were not widely available when BBJ was established, including whole-genome sequencing and multi-omics analysis.

4.6 Feature 5: Resources Are Available to Academic Researchers and Companies

BBJ provides biological samples and data for research that meets specified review and approval requirements.

Access is not limited to universities and public research institutions. Private-sector companies can also apply to use BBJ resources.

BBJ has also developed quality management and information security systems to support the continued use of its resources for research. [2][4]

5. What Scientific Achievements Has BBJ Produced?

According to BBJ's official reports, a cumulative total of 509 academic papers had been published using BBJ samples and information by the end of December 2025.

When secondary research using externally shared data and publicly available datasets is included, the total exceeds 600 publications. [1]

Two studies published in 2024 illustrate the scientific contributions of BBJ.

5.1 Discovery of Genetic Variants Relevant to Japanese Populations

A 2024 study published in Nature Genetics analyzed data from approximately 260,000 Japanese individuals, including BBJ participants.

The researchers identified 4,423 significant genetic loci associated with 63 quantitative traits.

Of these loci, 601 were newly identified.

The study demonstrated the importance of using genomic reference panels and statistical methods appropriate for Japanese populations.

5.2 Improving Genetic Risk Prediction for Type 2 Diabetes

Another 2024 study published in Nature Genetics combined data from BBJ and UK Biobank.

The researchers demonstrated that stratification by body mass index (BMI) could improve the predictive performance of polygenic risk scores (PRS) for type 2 diabetes.

Under certain conditions, improvements of up to 37% were reported.

This study also illustrates how Japanese and British biobanks can be used in complementary ways.

5.3 Scientific Publications Are Not the Same as Clinical Implementation

These achievements demonstrate that BBJ research has progressed beyond the initial identification of disease-associated genetic variants.

Its resources are increasingly being used to investigate disease mechanisms and develop risk prediction approaches relevant to personalized medicine.

However, it is important to distinguish between publishing scientific findings and successfully translating those findings into diagnostic methods or treatments used in clinical practice.

6. Comparing BBJ and UK Biobank

Comparing BBJ with UK Biobank provides a useful perspective on its distinctive strengths and limitations.

6.1 Key Differences Between BBJ and UK Biobank

Comparison BBJ UK Biobank
Establishment 2003 2003
Main operating organization Institute of Medical Science, The University of Tokyo UK Biobank (a UK charitable research organization)
Primary participants Patients with specific diseases Population-based volunteers aged 40–69 at recruitment
Number of participants Approximately 270,000 Approximately 500,000
Basic study design Hospital-based, disease-oriented cohort Population-based prospective cohort
Principal strengths Large numbers of disease cases, clinical information, Japanese genomic data Diverse health information, longitudinal follow-up, imaging and genetic data
Primary research objectives Disease mechanisms, genomic medicine, drug discovery Disease risk, preventive medicine, broad biomedical research
Current priorities Multi-omics, resource utilization, two-way participant engagement Enrichment of datasets, expansion of imaging and genomic information, long-term follow-up

Both biobanks have diversified their research activities over time. The table summarizes their fundamental design differences rather than imposing strict limitations on their possible uses. [1][3]

6.2 Differences in Research Design

The underlying research approaches can be summarized as follows.

BBJ

  1. Recruits patients with specific diseases through medical institutions.
  2. Collects DNA, clinical information, serum samples, and other research materials.
  3. Uses these resources to investigate disease mechanisms and support treatment-related research.

UK Biobank

  1. Recruits population-based volunteers.
  2. Collects genomic, lifestyle, imaging, clinical, and other health-related information.
  3. Uses these resources to investigate disease development, risk factors, and prevention.

This is a simplified representation of the original research designs. In practice, both biobanks support a wide range of biomedical research.

6.3 BBJ and UK Biobank Are Complementary Research Infrastructures

An important point is that BBJ and UK Biobank should not necessarily be considered substitutes for one another.

For example, researchers studying diabetes could use BBJ to investigate disease characteristics and genetic factors among patients.

They could then use UK Biobank to examine future disease risk and relationships with lifestyle factors in a population-based cohort.

This complementary approach can strengthen the interpretation and external validation of research findings.

7. Current Challenges Facing BBJ

To understand BBJ's future development, it is important to examine not only the scale of its research resources and its scientific achievements but also the challenges it currently faces.

The following discussion distinguishes between improvement priorities explicitly identified by BBJ or AMED and broader challenges inferred from BBJ's study design and publicly available information.

7.1 Challenge 1: Selection Bias Inherent in Disease-Oriented Cohorts

This is an important challenge arising from BBJ's research design.

BBJ participants are recruited from patients with specific diseases who receive care at participating medical institutions.

Consequently, the cohort does not necessarily represent the health status or disease distribution of the general population.

A 2017 study reported that the average age at enrollment in the first cohort was 62.7 years for men and 61.5 years for women.

The cohort also included patients who had already developed diseases and received treatment before enrollment. [3]

The main implications are as follows.

  • Because recruitment is based on patients receiving medical care, individuals with mild or undiagnosed conditions may be underrepresented.
  • When patients are enrolled after disease onset, it can be difficult to reconstruct environmental exposures and lifestyle characteristics before the disease developed.
  • Findings obtained from particular disease groups or age ranges may require further validation before being applied to healthy individuals or younger populations.

These limitations do not necessarily represent flaws in BBJ's design.

Rather, they reflect the trade-offs associated with efficiently recruiting large numbers of patients with specific diseases.

Collaboration with population-based biobanks is therefore likely to become increasingly important.

7.2 Challenge 2: Aging Participants and Maintaining Long-Term Relationships

BBJ has already begun taking steps to address this challenge.

More than 20 years have passed since BBJ began recruiting its first participants.

As participants age, die, transfer to other hospitals, stop receiving regular medical care, or change their contact information, maintaining long-term relationships becomes increasingly difficult.

To address this issue, BBJ launched "Minna no BBJ" in November 2024.

Beginning in January 2025, it started recruiting eligible existing participants for a new two-way biobank project at the following three hospitals. [6]

  • Juntendo University Hospital
  • Shonan Kamakura General Hospital
  • Nippon Medical School Hospital

According to the publicly available website as of November 2026, recruitment remained focused on these three hospitals.

This initiative represents an important change in the relationship between BBJ and its participants.

Traditionally, participants primarily provided samples and information for research.

The new approach seeks to establish ongoing relationships involving continued research participation, updates to health and lifestyle information, and communication of research findings.

However, this does not mean that all approximately 270,000 registered participants currently have access to the two-way engagement system.

7.3 Challenge 3: Transforming Stored Samples into High-Value Research Data

This is one of the major priorities of BBJ's fifth project phase.

BBJ stores extensive collections of DNA and serum samples.

However, as of April 2026, whole-genome sequencing and proteomics analyses had not been conducted for all participants.

For example, official figures indicate that whole-genome sequencing data were available for approximately 16,000 individuals, while proteomics data covered approximately 3,050 individuals, compared with approximately 270,000 registered patients. [2]

Using approximately 270,000 registered patients as the denominator, the approximate coverage rates are as follows.

Analysis type Individuals analyzed Approximate coverage
SNP Approximately 270,000 100%
Metabolomics Approximately 43,830 16.2%
Whole-genome sequencing Approximately 16,000 5.9%
Proteomics Approximately 3,050 1.1%

These percentages are approximate calculations based on publicly reported figures.

The denominator is approximately 270,000 registered patients, and the 100% figure for SNP data reflects a comparison between rounded official totals.

There may also be overlap between individuals included in different analyses, and the availability and quality of individual datasets are not necessarily uniform.

Additional analyses of existing samples could generate substantial new information.

However, this also introduces challenges involving analytical costs, quality control, selection of participants for specific research purposes, and standardization across different measurement technologies.

For multi-omics research in particular, the objective should not simply be to increase the quantity of data.

The data must also be integrated with clinical information in ways that produce reproducible and meaningful scientific findings.

7.4 Challenge 4: Balancing Data Accessibility and Security

BBJ provides samples and information to researchers through systems involving anonymization or identifier management, review procedures, and information security measures.

From a researcher's perspective, however, several practical questions are essential.

  • What types of samples and datasets are available?
  • What information is available about their quality and associated clinical characteristics?
  • How much time and administrative effort are required before research use can begin?

AMED has identified specific improvements related to promoting the use of BBJ resources.

These include making sample searches faster and more convenient from the researcher's perspective and providing clearer information about sample quality and associated clinical data. [4]

Simply possessing large amounts of data is not enough.

A biobank's competitiveness also depends on whether appropriate researchers can efficiently access the data they need through suitable and secure procedures.

7.5 Challenge 5: Sustainable Operations and Long-Term Funding

Operating a large-scale biobank requires continuous investment in several areas.

  • Long-term storage of biological samples
  • Equipment replacement and infrastructure upgrades
  • Data management
  • Information security
  • Provision of resources to researchers
  • Communication with participants

BBJ was initially established as a national research project with defined project periods.

It has since become a research infrastructure that has been maintained for more than two decades.

For such an infrastructure, securing stable funding and personnel while demonstrating scientific outputs and resource utilization is essential.

AMED's use of targets for sample distribution, resource utilization, and interim program evaluations reflects the importance of assessing the continued value and effectiveness of biobank infrastructure. [4]

However, publicly available information alone is insufficient to quantitatively assess BBJ's long-term financial position, potential future funding shortfalls, or the full costs of replacing its storage infrastructure.

These issues should therefore be understood as structural operational challenges rather than confirmed financial problems at BBJ.

7.6 Challenge 6: Translating Research Findings into Clinical Practice

BBJ has produced a substantial body of academic research.

An increasingly important question is how these findings can contribute to diagnostics, disease prevention, treatments, and drug discovery.

For example, even if researchers develop a genetic risk prediction model optimized for Japanese populations, several steps are required before it can be used in routine clinical care.

These include:

  • External validation of predictive accuracy
  • Evaluation of clinical utility
  • Assessment of cost-effectiveness

The multi-omics and two-way engagement initiatives in BBJ's fifth phase, together with AMED's B-cure NEXT initiative, are closely related to the broader challenge of translating research findings into practical applications. [1][5]

Genomic data contain highly sensitive personal information.

Such information may be stored for long periods and used in future research involving technologies or applications that did not exist when participants originally provided their consent.

Some analytical techniques and research applications now available were not fully anticipated when BBJ began more than 20 years ago.

This creates several important ethical considerations.

  • Ensuring consistency between the scope of original consent and current research applications
  • Providing appropriate information to participants
  • Managing withdrawal of consent
  • Determining how and when research results should be returned to participants

Through "Minna no BBJ," BBJ has developed features that allow participants to review their registered information, receive information about research results, and discontinue participation in research. [6]

These measures are important for maintaining participants' trust over the long term.

8. How Should BBJ's Current Challenges Be Prioritized?

Based on publicly available information, five areas appear particularly important for BBJ's future development.

Challenge Priority Potential measures
Enrichment of existing datasets Very high Integration of whole-genome and multi-omics data with clinical information
Greater utilization of research resources Very high Standardization of data searches, access procedures, and quality information
Ongoing participant relationships High Expansion of two-way platforms, ongoing consent management, and return of information
Collaboration with other biobanks High Data harmonization across different cohorts and external validation
Sustainable operations High Long-term funding, assessment of research value, and maintenance of equipment and personnel

These priority levels represent the assessment presented in this article and are not official rankings published by BBJ.

A particularly important observation is that BBJ is simultaneously working to increase the value of its existing stored samples and to deepen its ongoing relationships with research participants.

These two directions are complementary.

Additional analysis of stored samples can expand the types of scientific questions researchers are able to investigate.

At the same time, sustained relationships with participants may provide updated health and lifestyle information.

Together, these developments could substantially increase the clinical and scientific value of BBJ's resources.

9. Future Outlook and Overall Assessment

9.1 Three Major Transitions in BBJ's Development

BBJ's history of more than two decades can be understood through three major transitions.

Stage 1: Collecting Biological Samples

The initial priority was to establish large-scale cohorts of patients with specific diseases.

Stage 2: Making Samples and Data Available for Research

The next stage emphasized genetic discovery, genomic analysis, and providing research resources to academic institutions and companies.

Stage 3: Connecting Clinical Data, Omics Information, and Participants

The current direction emphasizes applications in drug discovery and diagnostics, ongoing updates to participant information, and the translation of research findings into healthcare benefits.

These transitions illustrate how the value of a research infrastructure increasingly depends not simply on the quantity of samples it stores, but on how those resources are used and how research outcomes are translated into benefits for society.

9.2 BBJ Does Not Need to Become Another UK Biobank

When comparing BBJ with UK Biobank, it is not necessarily appropriate to conclude that BBJ should adopt exactly the same structure.

Instead, BBJ may generate greater research value by strengthening its distinctive advantages, including large-scale patient data from Japanese populations, detailed disease-specific clinical information, and extensive stored biological samples.

Collaboration with population-based cohorts could further enhance these strengths.

Within Japan, important opportunities include collaboration with the Tohoku Medical Megabank Project (TMM) and the National Center Biobank Network (NCBN).

The B-cure NEXT initiative, launched in fiscal year 2026, also explicitly emphasizes such collaboration. [5]

9.3 How Should BBJ's Future Success Be Measured?

Overall, BBJ has achieved its initial objective of collecting biological samples from a large number of patients.

It is now undergoing a transition toward becoming a long-term research infrastructure supporting genomic medicine and drug discovery.

Future assessments of its success should therefore consider more than the number of registered patients or stored samples.

Important indicators include:

  • Actual utilization of research datasets and biological samples
  • Contributions to international collaborative research
  • Applications in drug discovery and diagnostics
  • Return of research benefits and information to participants

The value of BBJ should increasingly be assessed not only by how many samples and datasets it possesses, but also by how effectively those resources contribute to biomedical research and healthcare.

10. Conclusion: Toward a Sustainable Research Infrastructure Built on BBJ's Strengths

BioBank Japan was established in 2003 to advance personalized medicine in Japan.

Its initial objective was to recruit approximately 200,000 patients across 47 diseases and establish a research infrastructure focused primarily on identifying disease-associated genetic variants.

It subsequently expanded its activities through the development of a second cohort, accumulation of long-term follow-up data, external provision of research resources, and increasingly sophisticated genomic and multi-omics analyses.

Today, with approximately 270,000 registered patients, 51 target diseases, and approximately 440,000 registered disease cases, BBJ plays an important role in large-scale disease-oriented genomic research involving Japanese populations. [1][2]

At the same time, it faces several challenges.

These include selection bias inherent in disease-oriented cohorts, aging participants, data accessibility, long-term operational sustainability, and the translation of research findings into clinical applications.

Many of these challenges cannot be addressed independently.

Further development will require a combination of richer analysis of stored samples and clinical information, stronger two-way relationships with research participants, and collaboration with domestic and international biobanks.

In particular, BBJ and population-based research infrastructures such as UK Biobank should be viewed as complementary rather than necessarily competing resources.

For BBJ to continue developing successfully, it will be important to build on its distinctive strength in large-scale patient-derived samples and information while becoming a research infrastructure that is accessible to researchers, trusted by participants, and capable of generating tangible value for healthcare and drug discovery.

Two topics warrant particularly close examination in future research.

  1. Comparison of BBJ and UK Biobank in terms of funding structures, operating costs, and business models for providing research data and resources
  2. Assessment of the extent to which BBJ's research resources contribute to pharmaceutical and diagnostic development by private-sector companies

Investigating these questions would provide a more concrete understanding of BBJ's long-term sustainability and development potential.

This article is based on publicly available official materials and representative academic publications, with a research reference date of November 4, 2026.

Some aspects could not be adequately verified from public information alone, including the practical experiences of individual researchers, nonpublic operating costs, actual processing times for data access applications, and participant satisfaction.

References

[1] BioBank Japan, "History of BioBank Japan", Official BBJ Website. https://biobankjp.org/about/707

[2] BioBank Japan, "Available Samples and Information", Official BBJ Website. https://biobankjp.org/researchers/488

[3] Nagai A, Hirata M, Kamatani Y, et al., "Overview of the BioBank Japan Project: Study design and profile," Journal of Epidemiology, 27(3 Suppl), S2–S8, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5350590/

[4] Japan Agency for Medical Research and Development (AMED), "Genomic Research Biobank", Official AMED Website. https://www.amed.go.jp/program/03005/01_001_06.html

[5] Japan Agency for Medical Research and Development (AMED), "B-cure NEXT," Official AMED Website. https://www.amed.go.jp/program/03005/01_001.html

[6] BioBank Japan, "Minna no BBJ", Official BBJ Participant Website. https://mbbj.svc.biobankjp.org/